Rösch, F.
[Verfasser:in];
Herzog, H.
[Verfasser:in];
Stolz, B.
[Verfasser:in];
Brockmann, J.
[Verfasser:in];
Köhle, M.
[Verfasser:in];
Mühlensiepen, H.
[Verfasser:in];
Marbach, P.
[Verfasser:in];
Müller-Gärtner, H.-W.
[Verfasser:in]
Uptake kinetics of the somatostatin receptor ligand (86Y)DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
Uptake kinetics of the somatostatin receptor ligand (86Y)DOTA-DPhe1-Tyr3-octreotide ([86Y]SMT487) using positron emission tomography in non-human primates and calculation of radiation doses of the 90Y-labelled analogue
Beteiligte:
Rösch, F.
[Verfasser:in];
Herzog, H.
[Verfasser:in];
Stolz, B.
[Verfasser:in];
Brockmann, J.
[Verfasser:in];
Köhle, M.
[Verfasser:in];
Mühlensiepen, H.
[Verfasser:in];
Marbach, P.
[Verfasser:in];
Müller-Gärtner, H.-W.
[Verfasser:in]
Erschienen:
Springer-Verl., 1999
Erschienen in:European journal of nuclear medicine and molecular imaging 26, 353 - 366 (1999). ; European Journal of Nuclear Medicine; 1999, Vol. 26 Issue 4, p358
Anmerkungen:
Diese Datenquelle enthält auch Bestandsnachweise, die nicht zu einem Volltext führen.
Beschreibung:
[[sup 90]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide ([[sup 90]Y]SMT487) has been suggested as a promising radiotherapeutic agent for somatostatin receptor-expressing tumours. In order to quantify the in vivo parameters of this compound and the radiation doses delivered to healthy organs, the analogue [[sup 86]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide was synthesised and its uptake measured in baboons using positron emission tomography (PET). [[sup 86]Y]DOTADPhe[sup 1]-Tyr[sup 3]-octreotide was administered at two different peptide concentrations, namely 2 and 100 micro g peptide per m2 body surface. The latter concentration corresponded to a radiotherapeutic dose. In a third protocol [[sup 86]Y]DOTA-DPhe[sup 1]-Tyr[sup 3]-octreotide was injected in conjunction with a simultaneous infusion of an amino acid solution that was high in L-lysine in order to lower the renal uptake of radioyttrium.